MX352926B - Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. - Google Patents
Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.Info
- Publication number
- MX352926B MX352926B MX2013003594A MX2013003594A MX352926B MX 352926 B MX352926 B MX 352926B MX 2013003594 A MX2013003594 A MX 2013003594A MX 2013003594 A MX2013003594 A MX 2013003594A MX 352926 B MX352926 B MX 352926B
- Authority
- MX
- Mexico
- Prior art keywords
- vegf
- met
- treatment
- castration
- prostate cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Abstract
Esta invención se refiere al tratamiento del cáncer, particularmente cáncer de próstata resistente a la castración y metástasis osteoblásticas en los huesos, con un inhibidor doble de MET y VEGF.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38695910P | 2010-09-27 | 2010-09-27 | |
US201161481671P | 2011-05-02 | 2011-05-02 | |
PCT/US2011/053233 WO2012044572A1 (en) | 2010-09-27 | 2011-09-26 | Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013003594A MX2013003594A (es) | 2013-08-01 |
MX352926B true MX352926B (es) | 2017-12-14 |
Family
ID=44741730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013003594A MX352926B (es) | 2010-09-27 | 2011-09-26 | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. |
Country Status (22)
Country | Link |
---|---|
US (4) | US20140057943A1 (es) |
EP (1) | EP2621481B2 (es) |
JP (2) | JP6158705B2 (es) |
KR (1) | KR101882328B1 (es) |
CN (1) | CN103402505A (es) |
AR (1) | AR085195A1 (es) |
AU (2) | AU2011307304C1 (es) |
BR (1) | BR112013007220A2 (es) |
CA (1) | CA2812750C (es) |
DK (1) | DK2621481T4 (es) |
EA (1) | EA027476B1 (es) |
ES (1) | ES2754973T5 (es) |
FI (1) | FI2621481T4 (es) |
HU (1) | HUE045810T2 (es) |
IL (1) | IL225507B (es) |
MX (1) | MX352926B (es) |
PL (1) | PL2621481T5 (es) |
PT (1) | PT2621481T (es) |
SI (1) | SI2621481T2 (es) |
TW (2) | TW201738213A (es) |
UA (1) | UA114172C2 (es) |
WO (1) | WO2012044572A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013000980B1 (pt) | 2010-07-16 | 2022-08-16 | Exelixis, Inc | Composições farmacêuticas moduladoras de c-met |
DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
JP2014505109A (ja) | 2011-02-10 | 2014-02-27 | エクセリクシス, インク. | キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
TW201806598A (zh) | 2011-05-02 | 2018-03-01 | 艾克塞里克斯公司 | 治療癌症及骨癌疼痛之方法 |
BR112014006702A2 (pt) * | 2011-09-22 | 2017-06-13 | Exelixis Inc | método para tratar osteoporose |
DK2768796T3 (da) | 2011-10-20 | 2020-02-24 | Exelixis Inc | Fremgangsmåde til fremstilling af quinolin-derivater |
US20140323522A1 (en) * | 2011-11-08 | 2014-10-30 | Exelixis, Inc. | Method of Treating Cancer |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
CN103664776B (zh) * | 2012-09-26 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
US10273211B2 (en) | 2013-03-15 | 2019-04-30 | Exelixis, Inc. | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
WO2014165779A1 (en) * | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Drug combinations to treat cancer |
ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
KR102354963B1 (ko) | 2014-02-14 | 2022-01-21 | 엑셀리시스, 인코포레이티드 | N-{4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐}-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법 |
JP6666849B2 (ja) | 2014-03-17 | 2020-03-18 | エグゼリクシス, インコーポレイテッド | カボザンチニブ製剤の投与 |
CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
CN106573042A (zh) | 2014-08-05 | 2017-04-19 | 埃克塞里艾克西斯公司 | 治疗多发性骨髓瘤的药物组合 |
KR20170108822A (ko) * | 2016-03-18 | 2017-09-27 | 니혼 메디피직스 가부시키가이샤 | 조골형 골전이 모델 동물의 제조 방법 |
WO2017181187A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
CN108503650B (zh) * | 2017-02-27 | 2021-02-12 | 北京赛特明强医药科技有限公司 | 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用 |
JP7166292B2 (ja) | 2017-05-26 | 2022-11-07 | エグゼリクシス, インコーポレイテッド | N-{4-[(6,7-ジメトキシキノリン-4-イル)オキシ]フェニル}-n’-(4-フルオロフェニル)シクロプロパン-1,1-ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
CN111787939A (zh) | 2017-12-27 | 2020-10-16 | 圣朱德儿童研究医院有限公司 | 治疗castor相关疾病的方法 |
KR20200130242A (ko) | 2017-12-27 | 2020-11-18 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 판토테네이트 키나제의 소분자 조절제 |
KR20200115582A (ko) | 2018-01-26 | 2020-10-07 | 엑셀리시스, 인코포레이티드 | 키나제-의존성 장애의 치료용 화합물 |
KR102433023B1 (ko) * | 2018-02-11 | 2022-08-16 | 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 | 디옥시노퀴놀린 화합물, 이의 제조방법 및 용도 |
WO2022133034A1 (en) * | 2020-12-16 | 2022-06-23 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP1447405A4 (en) | 2001-10-17 | 2005-01-12 | Kirin Brewery | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS |
GB0219746D0 (en) | 2002-08-23 | 2002-10-02 | Inst Of Ex Botany Ascr | Azapurine derivatives |
ATE374199T1 (de) | 2002-10-21 | 2007-10-15 | Kirin Brewery | N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form |
JPWO2004039782A1 (ja) | 2002-10-29 | 2006-03-02 | 麒麟麦酒株式会社 | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
WO2004055004A1 (en) | 2002-12-13 | 2004-07-01 | Neurogen Corporation | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
WO2004054585A1 (en) | 2002-12-18 | 2004-07-01 | Pfizer Products Inc. | 4-anilino quinazoline derivatives for the treatment of abnormal cell growth |
AU2003299943A1 (en) | 2002-12-23 | 2004-07-22 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
AU2003292838A1 (en) | 2002-12-27 | 2004-07-29 | Kirin Beer Kabushiki Kaisha | Therapeutic agent for wet age-related macular degeneration |
EP1673085B1 (en) | 2003-09-26 | 2011-11-09 | Exelixis, Inc. | C-met modulators and methods of use |
JP5368701B2 (ja) | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
WO2008035209A2 (en) | 2006-05-30 | 2008-03-27 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
EP2101759B1 (en) | 2006-12-14 | 2018-10-10 | Exelixis, Inc. | Methods of using mek inhibitors |
US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
ES2635131T3 (es) * | 2007-08-29 | 2017-10-02 | Methylgene Inc. | Inhibidores de la actividad de la proteína tirosina cinasa |
TW200922590A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
CA2723617A1 (en) * | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
US20110229469A1 (en) | 2008-10-01 | 2011-09-22 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
CA2743416A1 (en) | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
JP2010126530A (ja) * | 2008-12-01 | 2010-06-10 | Takeda Chem Ind Ltd | 縮合複素環誘導体およびその用途 |
TW201028383A (en) | 2008-12-04 | 2010-08-01 | Exelixis Inc | Methods of preparing quinoline derivatives |
KR101733773B1 (ko) | 2009-01-16 | 2017-05-10 | 엑셀리시스, 인코포레이티드 | N-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
BR112012001118A2 (pt) | 2009-07-17 | 2016-02-23 | Exelixis Inc | formas cristalinas de n-[3-flúor-4-({6-(metilóxi)-7-[(3-morfolin-4-ilpropil)óxi]-quinolin-4-il}óxi)fenil]-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composição farmacêutica com as mesmas, métodos de preparação das mesmas e tratamento de câncer |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
EP2475390A4 (en) | 2009-09-09 | 2014-01-01 | Quintiles Transnat Corp | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS |
WO2011112896A1 (en) | 2010-03-12 | 2011-09-15 | Exelixis, Inc | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
BR112013000980B1 (pt) | 2010-07-16 | 2022-08-16 | Exelixis, Inc | Composições farmacêuticas moduladoras de c-met |
EP2593091A1 (en) | 2010-07-16 | 2013-05-22 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
CA2812744A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
JP2013540759A (ja) | 2010-09-27 | 2013-11-07 | エクセリクシス, インク. | 去勢抵抗性前立腺癌および造骨性転移の治療のためのmetおよびvegfの二元阻害薬 |
DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
CN103327979A (zh) | 2010-11-22 | 2013-09-25 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | 治疗癌症的方法 |
JP2014505109A (ja) | 2011-02-10 | 2014-02-27 | エクセリクシス, インク. | キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
TW201806598A (zh) | 2011-05-02 | 2018-03-01 | 艾克塞里克斯公司 | 治療癌症及骨癌疼痛之方法 |
TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
BR112014006702A2 (pt) | 2011-09-22 | 2017-06-13 | Exelixis Inc | método para tratar osteoporose |
DK2768796T3 (da) | 2011-10-20 | 2020-02-24 | Exelixis Inc | Fremgangsmåde til fremstilling af quinolin-derivater |
US20140323522A1 (en) | 2011-11-08 | 2014-10-30 | Exelixis, Inc. | Method of Treating Cancer |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
CN114129566A (zh) | 2012-09-07 | 2022-03-04 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
US10273211B2 (en) | 2013-03-15 | 2019-04-30 | Exelixis, Inc. | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
WO2014165779A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Drug combinations to treat cancer |
-
2011
- 2011-09-26 DK DK11764655.4T patent/DK2621481T4/da active
- 2011-09-26 KR KR1020137010372A patent/KR101882328B1/ko active IP Right Grant
- 2011-09-26 EP EP11764655.4A patent/EP2621481B2/en active Active
- 2011-09-26 UA UAA201305315A patent/UA114172C2/uk unknown
- 2011-09-26 PL PL11764655.4T patent/PL2621481T5/pl unknown
- 2011-09-26 CA CA2812750A patent/CA2812750C/en active Active
- 2011-09-26 US US13/876,290 patent/US20140057943A1/en not_active Abandoned
- 2011-09-26 MX MX2013003594A patent/MX352926B/es active IP Right Grant
- 2011-09-26 JP JP2013530386A patent/JP6158705B2/ja active Active
- 2011-09-26 ES ES11764655T patent/ES2754973T5/es active Active
- 2011-09-26 PT PT117646554T patent/PT2621481T/pt unknown
- 2011-09-26 SI SI201131802T patent/SI2621481T2/sl unknown
- 2011-09-26 EA EA201390465A patent/EA027476B1/ru not_active IP Right Cessation
- 2011-09-26 FI FIEP11764655.4T patent/FI2621481T4/fi active
- 2011-09-26 CN CN2011800565800A patent/CN103402505A/zh active Pending
- 2011-09-26 WO PCT/US2011/053233 patent/WO2012044572A1/en active Application Filing
- 2011-09-26 AU AU2011307304A patent/AU2011307304C1/en active Active
- 2011-09-26 HU HUE11764655A patent/HUE045810T2/hu unknown
- 2011-09-27 AR ARP110103539A patent/AR085195A1/es unknown
- 2011-09-27 TW TW106105784A patent/TW201738213A/zh unknown
- 2011-09-27 TW TW100134883A patent/TW201302709A/zh unknown
- 2011-11-26 BR BR112013007220A patent/BR112013007220A2/pt not_active IP Right Cessation
-
2013
- 2013-04-02 IL IL225507A patent/IL225507B/en active IP Right Grant
-
2015
- 2015-09-02 US US14/843,480 patent/US20160220554A1/en not_active Abandoned
-
2016
- 2016-07-08 AU AU2016204747A patent/AU2016204747A1/en not_active Abandoned
-
2017
- 2017-02-28 JP JP2017036322A patent/JP2017149714A/ja active Pending
-
2020
- 2020-06-18 US US16/905,307 patent/US11612597B2/en active Active
-
2023
- 2023-02-21 US US18/112,214 patent/US11969419B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013003594A (es) | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis de osteoblasticas en los huesosl. | |
MX2014005458A (es) | Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer. | |
GEP20156229B (en) | 5-alkynyl-pyrimidines | |
MX2015007205A (es) | Inhibidores de la desmetilasa de histona. | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
ECSP13012394A (es) | Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
PH12014502047A1 (en) | Treatment of cancer with tor kinase inhibitors | |
MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
WO2012065139A3 (en) | Entpd5 inhibitors | |
EP3079475A4 (en) | Glucocorticoid inhibitors for treatment of prostate cancer | |
EA201890598A3 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
IL221404A (en) | Inhibits thiogenethone-based autophagy based on cancer therapy | |
IN2014DN00254A (es) | ||
MX2013015357A (es) | Terapia de combinacion. | |
GB201012845D0 (en) | Inhibition of dicer function for treatment of cancer | |
EP2768512A4 (en) | ENZYME HAMMER FOR CANCER TREATMENT | |
RS56682B1 (sr) | Postupci primene egfr inhibitora | |
WO2012037553A9 (en) | Use of pkc-iota inhibitors for the treatment of breast cancer | |
NZ707930A (en) | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases | |
AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. | |
MX2013006526A (es) | Dosis de los derivados de arilsulfonamida. | |
JO3550B1 (ar) | مركب لمعالجة سرطان البروستاتا | |
TN2011000013A1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |